Regeneron Pharmaceuticals (NQ:REGN)

730.22 -4.98 (-0.68%)

Delayed Quote Updated: 2:36 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

66 67 Next >

The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

November 01, 2024

From The Law Offices of Frank R. Cruz

Via Business Wire

Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗

November 01, 2024

The major indexes declined, but haven't fallen apart.

Via Investor's Business Daily

Regeneron Earnings Top Views For Biotech Giant ↗

October 31, 2024

Shares of the biotech giant have been in a sharp slide.

Via Investor's Business Daily

$100 Invested In This Stock 15 Years Ago Would Be Worth $5,800 Today ↗

October 24, 2024

Via Benzinga

A Closer Look at 23 Analyst Recommendations For Regeneron Pharmaceuticals ↗

October 23, 2024

Via Benzinga

Why Is Regeneron Pharmaceuticals Stock Trading Lower Today? ↗

October 31, 2024

Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance.

Via Benzinga

Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday? ↗

October 31, 2024

Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months.

Via Benzinga

Regeneron Reports Third Quarter 2024 Financial and Operating Results

October 31, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology ↗

October 23, 2024

Via Benzinga

Market Whales and Their Recent Bets on REGN Options ↗

October 23, 2024

Via Benzinga

What the Options Market Tells Us About Regeneron Pharmaceuticals ↗

October 10, 2024

Via Benzinga

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗

October 30, 2024

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Via Benzinga

EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss ↗

October 28, 2024

EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients.

Via Benzinga

Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split ↗

October 28, 2024

One of these players has split its stock in the past. The other one hasn't.

Via The Motley Fool

Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent ↗

October 25, 2024

Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase 3b ADapt study results shared.

Via Benzinga

Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry ↗

October 09, 2024

Via Benzinga

A Closer Look at 24 Analyst Recommendations For Regeneron Pharmaceuticals ↗

October 04, 2024

Via Benzinga

Market Whales and Their Recent Bets on REGN Options ↗

October 03, 2024

Via Benzinga

Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI

October 24, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Seagate To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

October 23, 2024

Via Benzinga

Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise ↗

October 22, 2024

There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle.

Via Talk Markets

Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema

October 18, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest ↗

October 03, 2024

Via Benzinga

$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today ↗

September 30, 2024

Via Benzinga

Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce ↗

October 14, 2024

Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana.

Via Talk Markets

Here's How Much $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today ↗

October 10, 2024

Via Benzinga

These 3 Stocks Are Screaming Oversold: Seize the Opportunity

October 10, 2024

Micron, Biogen, and Regeneron are three stocks that appear oversold and could present substantial buying opportunities for investors seeking recovery plays.

Via MarketBeat

Topics ETFs Earnings

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗

October 09, 2024

The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...

Via Benzinga

Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs ↗

October 07, 2024

Regeneron's CSO George Yancopoulos warns that GLP-1 weight-loss drugs like Ozempic may lead to rapid muscle loss, increasing health risks. Regeneron is investigating therapies to offset these effects...

Via Benzinga

Should You Buy the Dip on This Top Growth Stock? ↗

October 05, 2024

The biotech needs to overcome an issue most drugmakers face at some point.

Via The Motley Fool

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

66 67 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.